United States, California, San Jose - 03/29/2021 — March 29, 2021 (San Jose, California) – PreciGenome, LLC (“PreciGenome”), a global leader in the development of innovative molecular diagnostic assays and instruments, has released the FastPlex Triplex SARS-Cov-2 set of assays for the detection of the most prevalent COVID-19 mutations including UK B.1.1.7, Brazil P1, and South Africa B.1.351 variants. The assays, which are compatible with industry leading PCR machines, have been CE-IVD approved for sale in Europe and are available in the US when designated as RUO.
The mutation suite is a collection of four separate assays that can be deployed either separately or sequentially depending on both instrument type and the specific sets of mutations a lab is attempting to determine.
According to Brad Morgan, Chief Business Officer and Head of Business Development for PreciGenome: “These variants, especially UK B.1.1.7, have absolutely ravaged Europe and parts of the United States. Labs are looking for an efficient and reliable way to both retrospectively test stored samples and determine the presence of mutation in new patients. Variant testing is mandatory in many countries in Europe and the labs doing these tests simply do not have the right assays as their disposal. We therefore developed our mutation suite to meet the demands of current and future customers.”
About PreciGenome: Headquartered in San Jose with offices in Düsseldorf, Hong Kong, Suzhou, Delhi and Moscow, PreciGenome is an innovative medical technology company lead by an acclaimed team of Silicon Valley scientists dedicated to the transformation and application of microfluidics technologies to provide solutions for molecular biology.
Media Contacts:Company Name: PreciGenome LLC